| Net profit of Strides Pharma Science rose 54.45% to Rs 126.94 crore in the quarter ended March 2026 as against Rs 82.19 crore during the previous quarter ended March 2025. Sales rose 11.18% to Rs 1323.47 crore in the quarter ended March 2026 as against Rs 1190.39 crore during the previous quarter ended March 2025.
For the full year,net profit declined 84.52% to Rs 556.19 crore in the year ended March 2026 as against Rs 3593.46 crore during the previous year ended March 2025. Sales rose 6.43% to Rs 4858.68 crore in the year ended March 2026 as against Rs 4565.34 crore during the previous year ended March 2025.
| Particulars | Quarter Ended | Year Ended | | Mar. 2026 | Mar. 2025 | % Var. | Mar. 2026 | Mar. 2025 | % Var. |
| Sales | 1323.47 | 1190.39 | 11 | 4858.68 | 4565.34 | 6 |
| OPM % | 18.11 | 18.30 | - | 19.04 | 17.58 | - |
| PBDT | 207.71 | 182.66 | 14 | 897.93 | 614.52 | 46 |
| PBT | 154.46 | 133.80 | 15 | 695.53 | 422.26 | 65 |
| NP | 126.94 | 82.19 | 54 | 556.19 | 3593.46 | -85 |
|